Jana L Hirschtick1, Andrea R Titus1, Elizabeth Slocum1, Laura E Power1, Robert E Hirschtick2, Michael R Elliott3,4, Patricia McKane5, Nancy L Fleischer1. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA. 2. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA. 4. Survey Research Center, Institute for Social Research, Ann Arbor, Michigan, USA. 5. Lifecourse Epidemiology and Genomics Division, Michigan Department of Health and Human Services, Lansing, Michigan, USA.
Abstract
BACKGROUND: Emerging evidence suggests many people have persistent symptoms after acute coronavirus disease 2019 (COVID-19) illness. Our objective was to estimate the prevalence and correlates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC). METHODS: We used a population-based probability survey of adults with COVID-19 in Michigan. Living noninstitutionalized adults aged ≥18 in the Michigan Disease Surveillance System with COVID-19 onset through mid-April 2020 were eligible for selection (N = 28 000). Among 2000 selected, 629 completed the survey between June-December 2020. We estimated PASC prevalence, defined as persistent symptoms ≥30 (30-day COVID-19) or ≥60 (60-day COVID-19) days post-COVID-19 onset, overall and by sociodemographic and clinical factors. We used modified Poisson regression to produce adjusted prevalence ratios (aPRs) for potential risk factors. RESULTS: The analytic sample (n = 593) was predominantly female (56.1%), aged ≥45 years (68.2%), and non-Hispanic White (46.3%) or Black (34.8%). Thirty- and 60-day COVID-19 were highly prevalent (52.5% and 35.0%), even among nonhospitalized respondents (43.7% and 26.9%) and respondents reporting mild symptoms (29.2% and 24.5%). Respondents reporting very severe (vs mild) symptoms had 2.25 times higher prevalence of 30-day COVID-19 (aPR, 2.25; 95% CI, 1.46-3.46) and 1.71 times higher prevalence of 60-day COVID-19 (aPR, 1.71; 95% CI: 1.02-2.88). Hospitalized (vs nonhospitalized) respondents had ~40% higher prevalence of both 30-day (aPR, 1.37; 95% CI: 1.12-1.69) and 60-day (aPR, 1.40; 95% CI: 1.02-1.93) COVID-19. CONCLUSIONS: PASC is highly prevalent among cases reporting severe initial symptoms and, to a lesser extent, cases reporting mild and moderate symptoms.
BACKGROUND: Emerging evidence suggests many people have persistent symptoms after acute coronavirus disease 2019 (COVID-19) illness. Our objective was to estimate the prevalence and correlates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC). METHODS: We used a population-based probability survey of adults with COVID-19 in Michigan. Living noninstitutionalized adults aged ≥18 in the Michigan Disease Surveillance System with COVID-19 onset through mid-April 2020 were eligible for selection (N = 28 000). Among 2000 selected, 629 completed the survey between June-December 2020. We estimated PASC prevalence, defined as persistent symptoms ≥30 (30-day COVID-19) or ≥60 (60-day COVID-19) days post-COVID-19 onset, overall and by sociodemographic and clinical factors. We used modified Poisson regression to produce adjusted prevalence ratios (aPRs) for potential risk factors. RESULTS: The analytic sample (n = 593) was predominantly female (56.1%), aged ≥45 years (68.2%), and non-Hispanic White (46.3%) or Black (34.8%). Thirty- and 60-day COVID-19 were highly prevalent (52.5% and 35.0%), even among nonhospitalized respondents (43.7% and 26.9%) and respondents reporting mild symptoms (29.2% and 24.5%). Respondents reporting very severe (vs mild) symptoms had 2.25 times higher prevalence of 30-day COVID-19 (aPR, 2.25; 95% CI, 1.46-3.46) and 1.71 times higher prevalence of 60-day COVID-19 (aPR, 1.71; 95% CI: 1.02-2.88). Hospitalized (vs nonhospitalized) respondents had ~40% higher prevalence of both 30-day (aPR, 1.37; 95% CI: 1.12-1.69) and 60-day (aPR, 1.40; 95% CI: 1.02-1.93) COVID-19. CONCLUSIONS: PASC is highly prevalent among cases reporting severe initial symptoms and, to a lesser extent, cases reporting mild and moderate symptoms.
Authors: Hannah E Maier; Guillermina Kuan; Saira Saborio; Fausto Andres Bustos Carrillo; Miguel Plazaola; Carlos Barilla; Nery Sanchez; Roger Lopez; Matt Smith; John Kubale; Sergio Ojeda; Julio C Zuniga-Moya; Bradley Carlson; Brenda Lopez; Anna M Gajewski; Mahboob Chowdhury; Eva Harris; Angel Balmaseda; Aubree Gordon Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: César Fernández-de-Las-Peñas; José D Martín-Guerrero; Lidiane L Florencio; Esperanza Navarro-Pardo; Jorge Rodríguez-Jiménez; Juan Torres-Macho; Oscar J Pellicer-Valero Journal: Infection Date: 2022-04-22 Impact factor: 7.455
Authors: James B O'Keefe; H Caroline Minton; Mary Morrow; Colin Johnson; Miranda A Moore; Ghazala A D O'Keefe; Karima Benameur; Jason Higdon; Jessica K Fairley Journal: Open Forum Infect Dis Date: 2021-07-27 Impact factor: 3.835
Authors: Nikhil Ram-Mohan; David Kim; Angela J Rogers; Catherine A Blish; Kari C Nadeau; Andra L Blomkalns; Samuel Yang Journal: medRxiv Date: 2021-09-07
Authors: Yu-Hsiang Hsieh; Richard E Rothman; Sunil S Solomon; Mark Anderson; Michael Stec; Oliver Laeyendecker; Isabel V Lake; Reinaldo E Fernandez; Gaby Dashler; Radhika Mehta; Thomas Kickler; Gabor D Kelen; Shruti H Mehta; Gavin A Cloherty; Thomas C Quinn Journal: Open Forum Infect Dis Date: 2022-03-16 Impact factor: 3.835
Authors: Nikhil Ram-Mohan; David Kim; Angela J Rogers; Catherine A Blish; Kari C Nadeau; Andra L Blomkalns; Samuel Yang Journal: Open Forum Infect Dis Date: 2021-12-25 Impact factor: 3.835